Emory Medicine Laser Capture Microdissection Facility

埃默里医学激光捕获显微切割设备

• 批准号: 6440797
• 负责人: CURT H. HAGEDORN
• 金额: $ 13.15万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6440797
• 关键词: biomedical equipment purchase; cytology; laser capture microdissection

The information in the human genome database promises to provide a new means to investigate human diseases. However, a limiting factor in using this database in identifying new diagnostic/prognostic markers and defining the molecular mechanisms of disease is the challenge of isolating specific cell populations and their mRNA from clinical tissue biopsies Investigators have isolated specific cell types from small samples of tissue using micropipette dissection methods. However, they require a high degree of manual skill and are time-consuming. A Laser Capture Microdissection (LCM) system was developed at NIH to meet this challenge and more rapidly isolate specific cells from clinical biopsy samples. By combining LCM with non-thermophilic RNA amplification methods it is now possible to produce aRNA from 100-1,000 cells and probe high-density arrays for in vivo functional genomic studies of specific cells in clinical biopsies. The Emory Medicine LCM facility will be incorporated into the Vascular Medical Center at Emory University. It will be used to investigate gene expression of specific cell types in a variety of chronic inflammatory diseases such as atherosclerosis, hepatitis C, graft vs. host disease following stem cell transplantation, and studies regarding the in vivo source of actor VIII during chronic liver disease. Specific programs that will utilize the LCM facility include: 1) Comparing gene expression within Kupffer, endothelial stellate, and T cells in liver biopsy samples of control patients and those with chronic hepatitis C (acute vs. chronic; siblings with non-progressive vs. severe progressive inflammation/fibrosis; responders vs. non-responders to treatment); 2) Studying the modulation of gene expression in individual endothelial cells in humans and experimental animals exposed to different hemodynamic milieus and treatments; 3) Studying the in vivo gene expression of vascular adventitial myofibroblasts during post- angioplasty restenosis; 4) Studying the in vivo expression of vascular adventitial myofibroblasts during post-angioplasty restenosis; 4) Studying gene expression of Factor VIII in liver endothelial and parenchyma cells during chronic liver diseases; 5) studying the in vivo gene expression of endothelial cells of proliferating vs. regressing hemangiomas; and 6) studying the in vivo gene expression of human dermal endothelial cells during cutaneous inflammatory diseases.

人类基因组数据库中的信息有望提供一种新手段来调查人类疾病。然而，使用该数据库鉴定新的诊断/预后标记并定义疾病的分子机制的一个限制因素是分离特定细胞群体及其从临床组织活检研究者中的mRNA的挑战，它们使用微孔解析方法将特定细胞类型与小样品分离出来。但是，它们需要高度的手动技能，并且耗时。在NIH上开发了激光捕获显微解剖（LCM）系统，以应对这一挑战，并从临床活检样品中更快地分离了特定的细胞。通过将LCM与非嗜热RNA扩增方法相结合，现在可以从100-1,000个细胞中产生ARNA，并为临床活检中特定细胞的体内功能基因组研究探测高密度阵列。 Emory Medicine LCM设施将纳入Emory University的血管医学中心。它将用于研究各种慢性炎性疾病中特定细胞类型的基因表达，例如动脉粥样硬化，乙型肝炎，干细胞移植后的肝病与宿主疾病，以及有关慢性肝病期间参与者VIII的体内VIII的研究。将利用LCM设施的特定程序包括：1）在对照患者的肝活检样本中比较基因表达，内皮静脉内和T细胞，以及患有慢性乙型肝炎的患者（急性与慢性;兄弟姐妹均具有严重的渐进式炎症/纤维化/纤维纤维症； erseversive;兄弟姐妹; 2）研究人类各个内皮细胞中基因表达的调节，以及暴露于不同血液动力学环境和治疗的实验动物； 3）研究血管成形术后血管成形术期间血管外生肌纤维细胞的体内基因表达； 4）研究血管成形术后血管成形术期间血管外生肌纤维细胞的体内表达； 4）研究慢性肝病期间肝内皮和实质细胞中VIII因子的基因表达； 5）研究增生与恢复血管瘤的内皮细胞的体内基因表达； 6）研究皮肤炎症性疾病期间人真皮内皮细胞的体内基因表达。